NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX) today announced that data from pre-clinical studies of its PRTX-100 compound in development for the treatment of autoimmune and inflammatory diseases, demonstrated efficacy in well-established murine (mouse) models of rheumatoid arthritis. The data from the pre-clincial studies were presented today by Joe J. Dervan, Ph.D., Director of Protein Chemistry and Biopharmaceutical Manufacturing at Protalex, at the Fifth International Conference on Autoimmune Disorders in Sorrento, Italy.
